Literature DB >> 12605456

Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42.

Daniel H S Lee1, Hoau-Yan Wang.   

Abstract

The beta-amyloid peptides (Abeta), Abeta(1-40) and Abeta(1-42), have been implicated in Alzheimer's disease (AD) pathology. Although Abeta(1-42) is generally considered to be the pathological peptide in AD, both Abeta(1-40) and Abeta(1-42) have been used in a variety of experimental models without discrimination. Here we show that monomeric or oligomeric forms of the two Abeta peptides, when interact with the neuronal cation channel, alpha7 nicotinic acetylcholine receptors (alpha7nAChR), would result in distinct physiologic responses as measured by acetylcholine release and calcium influx experiments. While Abeta(1-42) effectively attenuated these alpha7nAChR-dependent physiology to an extent that was apparently irreversible, Abeta(1-40) showed a lower inhibitory activity that could be restored upon washings with physiologic buffers or treatment with alpha7nAChR antagonists. Our data suggest a clear pharmacological distinction between Abeta(1-40) and Abeta(1-42). Copyright 2003 Wiley Periodicals, Inc. J Neurobiol 55: 25-30, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605456     DOI: 10.1002/neu.10203

Source DB:  PubMed          Journal:  J Neurobiol        ISSN: 0022-3034


  18 in total

Review 1.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Authors:  Patricia Spilman; Olivier Descamps; Olivia Gorostiza; Clare Peters-Libeu; Karen S Poksay; Alexander Matalis; Jesus Campagna; Alexander Patent; Rammohan Rao; Varghese John; Dale E Bredesen
Journal:  Brain Res       Date:  2013-12-31       Impact factor: 3.252

Review 3.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

4.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

5.  Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus.

Authors:  Nolan R Campbell; Catarina C Fernandes; Andrew W Halff; Darwin K Berg
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

Review 6.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 7.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

Review 8.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 9.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

10.  β-Amyloid-evoked apoptotic cell death is mediated through MKK6-p66shc pathway.

Authors:  Muneesa Bashir; Arif A Parray; Rafia A Baba; Hina F Bhat; Sehar S Bhat; Umar Mushtaq; Khurshid I Andrabi; Firdous A Khanday
Journal:  Neuromolecular Med       Date:  2013-10-02       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.